record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
G207 phase I pediatric high-grade glioma trial, New England Journal of Medicine
authors
reviewer:will-blair
Oncolytic HSV-1 G207 phase I pediatric HGG trial achieved 12.2-month median OS (5 of 12 patients >18 months survival) without dose-limiting toxicities—mechanism (lytic immunity + oncolytic spread) is distinct from chemotherapy and demonstrates mechanism-appropriate design necessity.
vs_4ba55a2840324e28 · manual_curation
outgoing
vf_b634c43d011f00b1Late radiation toxicity and secondary malignancy risk compound inadequate efficacy of adult-scaled HGG regimens
incoming
No incoming links.
events
vev_d84e237bb0bb5896finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_54a3b6bdf0aa18cefinding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.